Login to Your Account

Washington Roundup

FDA Questions Risk-Benefit of Ariad's Cancer Drug

By Mari Serebrov
Washiington Editor

Monday, March 19, 2012
WASHINGTON – Ariad Pharmaceuticals Inc. will have a lot on the line Tuesday when an FDA advisory committee takes a hard look at the data for its sarcoma drug Taltorivc. But for the FDA, it all comes down to one question – do the risks outweigh the benefits?

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription